USA - engelsk - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib 200 mg - celecoxib capsules  are indicated for the management of the signs and symptoms of oa [see clinical studies (14.1)] for the management of the signs and symptoms of ra [see clinical studies (14.2)] for the management of the signs and symptoms of jra in patients 2 years and older [see clinical studies (14.3)] for the management of the signs and symptoms of as [see clinical studies (14.4)] for the management of acute pain in adults [see clinical studies (14.5)] for the management of primary dysmenorrhea [see clinical studies (14.5)] celecoxib is contraindicated in the following patients: pregnancy category c. pregnancy category d from 30 weeks of gestation onward. risk summary use of nsaids, including celecoxib, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. avoid use of nsaids, including celecoxib, in pregnant women starting at 30 weeks of gestation. there are no adequate and well-controlled studies of celecoxib in pregnant women. data from observa

USA - engelsk - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib 100 mg - celecoxib capsules are indicated for the management of the signs and symptoms of oa [ see clinical studies (14.1) ] for the management of the signs and symptoms of ra [ see clinical studies (14.2) ] for the management of the signs and symptoms of jra in patients 2 years and older [ see clinical studies (14.3) ] for the management of the signs and symptoms of as [ see clinical studies (14.4) ] for the management of acute pain in adults [ see clinical studies (14.5) ] for the management of primary dysmenorrhea [ see clinical studies (14.5) ] celecoxib capsules are contraindicated in the following patients : - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib, any components of the drug product [see warnings and precautions (5.7, 5.9) ]. - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids, have been reported in such patients [ see warnings and precautions

USA - engelsk - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib 200 mg - celecoxib is contraindicated in the following patients : pregnancy category c. pregnancy category d from 30 weeks of gestation onward. risk summary use of nsaids, including celecoxib, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. avoid use of nsaids, including celecoxib, in pregnant women starting at 30 weeks of gestation. there are no adequate and well-controlled studies of celecoxib in pregnant women. data from observational studies regarding potential embryofetal risks of nsaid use in women in the first or second trimesters of pregnancy are inconclusive. in the general u.s. population, all clinically recognized pregnancies, regardless of drug exposure, have a background rate of 2–4% for major malformations, and 15–20% for pregnancy loss. in animal reproduction studies, embryo-fetal deaths and an increase in diaphragmatic hernias were observed in rats administered celecoxib daily during the period of organogenesis at oral doses approximately

USA - engelsk - NLM (National Library of Medicine)

american health packaging - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib 100 mg - celecoxib capsules are indicated for the management of the signs and symptoms of oa [ see clinical studies ( 14.1) ]. for the management of the signs and symptoms of ra [ see clinical studies ( 14.2) ]. for the management of the signs and symptoms of jra in patients 2 years and older [ see clinical studies ( 14.3) ]. for the management of the signs and symptoms of as [ see clinical studies ( 14.4) ]. for the management of acute pain in adults [ see clinical studies ( 14.5) ]. for the management of primary dysmenorrhea [ see clinical studies ( 14.5) ]. celecoxib is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib, any components of the drug product [ see warnings and precautions ( 5.7, 5.9) ]. - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids, have been reported in such patients [ see warnings and precauti

USA - engelsk - NLM (National Library of Medicine)

proficient rx lp - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib 100 mg - carefully consider the potential benefits and risks of celecoxib capsules and other treatment options before deciding to use celecoxib capsules. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [see warnings and precautions (5)]  celecoxib capsules is indicated for relief of the signs and symptoms of oa [see clinical studies (14.1)] celecoxib capsules is indicated for relief of the signs and symptoms of ra [see clinical studies (14.2)] celecoxib capsules is indicated for relief of the signs and symptoms of jra in patients 2 years and older [see clinical studies (14.3)] celecoxib capsules is indicated for the relief of signs and symptoms of as [see clinical studies (14.4)] celecoxib capsules is indicated for the management of ap in adults [see clinical studies (14.5)] celecoxib capsules is indicated for the treatment of pd [see clinical studies (14.5)] celecoxib capsules is contraindicated: pregnancy category c. pregnancy category d from 30 weeks of ges

USA - engelsk - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib 200 mg - celecoxib capsules are indicated for the management of the signs and symptoms of oa [ see clinical studies (14.1) ] for the management of the signs and symptoms of ra [ see clinical studies (14.2) ] for the management of the signs and symptoms of jra in patients 2 years and older [ see clinical studies (14.3) ] for the management of the signs and symptoms of as [ see clinical studies (14.4) ] for the management of acute pain in adults [ see clinical studies (14.5) ] for the management of primary dysmenorrhea [ see clinical studies (14.5) ] celecoxib capsules are contraindicated in the following patients : - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib, any components of the drug product [see warnings and precautions (5.7, 5.9) ]. - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids, have been reported in such patients [ see warnings and precautions

USA - engelsk - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib 100 mg - celecoxib is indicated for the management of the signs and symptoms of oa [see clinical studies (14.1) ] for the management of the signs and symptoms of ra [see clinical studies (14.2) ] for the management of the signs and symptoms of jra in patients 2 years and older [see clinical studies (14.3) ] for the management of the signs and symptoms of as [see clinical studies (14.4) ] for the management of acute pain in adults [see clinical studies (14.5) ] for the management of primary dysmenorrhea [see clinical studies (14.5) ] celecoxib is contraindicated in the following patients: pregnancy category c. pregnancy category d from 30 weeks of gestation onward. risk summary use of nsaids, including celecoxib, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. avoid use of nsaids, including celecoxib, in pregnant women starting at 30 weeks of gestation. there are no adequate and well-controlled studies of celecoxib in pregnant women. data from observationa

USA - engelsk - NLM (National Library of Medicine)

rxchange co. - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib 200 mg - carefully consider the potential benefits and risks of celecoxib and other treatment options before deciding to use celecoxib capsules. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [ see warnings and precautions (5) ] celecoxib capsules are indicated for relief of the signs and symptoms of oa [ see clinical studies (14.1) ] celecoxib capsules are indicated for relief of the signs and symptoms of ra [ see clinical studies (14.2) ] celecoxib capsules are indicated for relief of the signs and symptoms of jra in patients 2 years and older [ see clinical studies (14.3) ] celecoxib capsules are indicated for the relief of signs and symptoms of as [ see clinical studies (14.4) ] celecoxib capsules are indicated for the management of ap in adults [ see clinical studies (1

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - celecoxib -

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - celecoxib -